Extended-release trazodone in the treatment of major depressive disorder


Karamustafalioglu O., Dilbaz N., Caykoylu A., ALKIN T., GÖNÜL A. S. , ATMACA M.

ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, vol.20, no.5, pp.453-459, 2019 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Review
  • Volume: 20 Issue: 5
  • Publication Date: 2019
  • Doi Number: 10.5455/apd.302644467
  • Title of Journal : ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY
  • Page Numbers: pp.453-459

Abstract

Major depressive disorder is a common psychiatric disorder. The aim of the treatment is to improve daily functions with remissions in symptoms, and antidepressants are the first-line treatments for a major depressive episode (moderate-severe depressive episode). In this paper, the pharmacological properties, clinical efficacy and safety of extended-release trazodone (TzCOAD) are studied. Expert opinion: A single daily dose of TzCOAD may provide similar efficacy and increased tolerability to immediate-release trazodone (TzIR) and other antidepressants.